Possible involvement of stress-activated protein kinase signaling pathway and fas receptor expression in prevention of ischemia/reperfusion- induced cardiomyocyte apoptosis by carvedilol

Tian Li Yue, Xin Liang Ma, Xinkang Wang, Anne M. Romanic, Gao Lin Liu, Calvert Louden, Juan Li Gu, Sanjay Kumar, George Poste, Robert R. Ruffolo, Giora Z. Feuerstein

Research output: Contribution to journalArticle

227 Citations (Scopus)

Abstract

Carvedilol, a new vasodilating β-adrenoceptor antagonist and a potent antioxidant, produces a high degree of cardioprotection in a variety of experimental models of ischemic cardiac injury. Recent clinical studies in patients with heart failure have demonstrated that carvedilol reduces morbidity and mortality and inhibits cardiac remodeling. The present study was designed to explore whether the protective effects of carvedilol on the ischemic myocardium include inhibition of apoptosis of cardiomyocytes and, if so, to determine its mechanism of action. Anesthetized rabbits were subjected to 30 minutes of coronary artery occlusion followed by 4 hours of reperfusion. Detection of apoptosis of cardiomyocytes was based on the presence of nucleosomal DNA fragments on agarose gels (DNA ladder) and in situ nick end labeling. Carvedilol (1 mg/kg IV), administered 5 minutes before reperfusion, reduced the number of apoptotic myocytes in the ischemic area from 14.7±0.4% to 3.4±1.8% (77% reduction, P<.001). Propranolol, administered at equipotent β-blocking dosage, reduced the number of apoptotic myocytes to 8.94±2.1% (39% reduction, P<.05). DNA ladders were observed in the hearts of all six vehicle-treated rabbits but only one of six carvedilol-treated rabbits (P<.01). Immunocytochemical analysis of rabbit hearts demonstrated an upregulation of Fas protein in ischemic cardiomyocytes, and treatment with carvedilol reduced both the intensity of staining as well as the area stained. Myocardial ischemia/reperfusion led to a rapid activation of stress-activated protein kinase (SAPK) in the ischemic area but not in nonischemic regions. SAPK activity was increased from 2.1±0.3 mU/mg (basal) to 8.9±0.8 mU/mg after 30 minutes of ischemia followed by 20 minutes of reperfusion. Carvedilol inhibited the activation of SAPK by 53.4±6.5% (P<.05). Under the same conditions, propranolol (1 mg/kg) had no effect on SAPK activation. Taken together, these results suggest that carvedilol prevents myocardial ischemia/reperfusion-induced apoptosis in cardiomyocytes possibly by downregulation of the SAPK signaling pathway, by inhibition of Fas receptor expression, and by β-adrenergic blockade. The former two actions represent novel and important mechanisms that may contribute to the cardioprotective effects of carvedilol.

Original languageEnglish (US)
Pages (from-to)166-174
Number of pages9
JournalCirculation Research
Volume82
Issue number2
StatePublished - Feb 9 1998
Externally publishedYes

Fingerprint

CD95 Antigens
Heat-Shock Proteins
Cardiac Myocytes
Protein Kinases
Reperfusion
Ischemia
Apoptosis
Rabbits
Myocardial Reperfusion
Propranolol
Muscle Cells
Myocardial Ischemia
DNA
carvedilol
Coronary Occlusion
In Situ Nick-End Labeling
Adrenergic Agents
Sepharose
Adrenergic Receptors
Coronary Vessels

Keywords

  • Apoptosis
  • Cardiomyocyte
  • Fas
  • Ischemia
  • Reperfusion
  • Stress-activated protein kinase

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Possible involvement of stress-activated protein kinase signaling pathway and fas receptor expression in prevention of ischemia/reperfusion- induced cardiomyocyte apoptosis by carvedilol. / Yue, Tian Li; Ma, Xin Liang; Wang, Xinkang; Romanic, Anne M.; Liu, Gao Lin; Louden, Calvert; Gu, Juan Li; Kumar, Sanjay; Poste, George; Ruffolo, Robert R.; Feuerstein, Giora Z.

In: Circulation Research, Vol. 82, No. 2, 09.02.1998, p. 166-174.

Research output: Contribution to journalArticle

Yue, TL, Ma, XL, Wang, X, Romanic, AM, Liu, GL, Louden, C, Gu, JL, Kumar, S, Poste, G, Ruffolo, RR & Feuerstein, GZ 1998, 'Possible involvement of stress-activated protein kinase signaling pathway and fas receptor expression in prevention of ischemia/reperfusion- induced cardiomyocyte apoptosis by carvedilol', Circulation Research, vol. 82, no. 2, pp. 166-174.
Yue, Tian Li ; Ma, Xin Liang ; Wang, Xinkang ; Romanic, Anne M. ; Liu, Gao Lin ; Louden, Calvert ; Gu, Juan Li ; Kumar, Sanjay ; Poste, George ; Ruffolo, Robert R. ; Feuerstein, Giora Z. / Possible involvement of stress-activated protein kinase signaling pathway and fas receptor expression in prevention of ischemia/reperfusion- induced cardiomyocyte apoptosis by carvedilol. In: Circulation Research. 1998 ; Vol. 82, No. 2. pp. 166-174.
@article{0663c1afe5f542c1b3dc23d1dbf9fe82,
title = "Possible involvement of stress-activated protein kinase signaling pathway and fas receptor expression in prevention of ischemia/reperfusion- induced cardiomyocyte apoptosis by carvedilol",
abstract = "Carvedilol, a new vasodilating β-adrenoceptor antagonist and a potent antioxidant, produces a high degree of cardioprotection in a variety of experimental models of ischemic cardiac injury. Recent clinical studies in patients with heart failure have demonstrated that carvedilol reduces morbidity and mortality and inhibits cardiac remodeling. The present study was designed to explore whether the protective effects of carvedilol on the ischemic myocardium include inhibition of apoptosis of cardiomyocytes and, if so, to determine its mechanism of action. Anesthetized rabbits were subjected to 30 minutes of coronary artery occlusion followed by 4 hours of reperfusion. Detection of apoptosis of cardiomyocytes was based on the presence of nucleosomal DNA fragments on agarose gels (DNA ladder) and in situ nick end labeling. Carvedilol (1 mg/kg IV), administered 5 minutes before reperfusion, reduced the number of apoptotic myocytes in the ischemic area from 14.7±0.4{\%} to 3.4±1.8{\%} (77{\%} reduction, P<.001). Propranolol, administered at equipotent β-blocking dosage, reduced the number of apoptotic myocytes to 8.94±2.1{\%} (39{\%} reduction, P<.05). DNA ladders were observed in the hearts of all six vehicle-treated rabbits but only one of six carvedilol-treated rabbits (P<.01). Immunocytochemical analysis of rabbit hearts demonstrated an upregulation of Fas protein in ischemic cardiomyocytes, and treatment with carvedilol reduced both the intensity of staining as well as the area stained. Myocardial ischemia/reperfusion led to a rapid activation of stress-activated protein kinase (SAPK) in the ischemic area but not in nonischemic regions. SAPK activity was increased from 2.1±0.3 mU/mg (basal) to 8.9±0.8 mU/mg after 30 minutes of ischemia followed by 20 minutes of reperfusion. Carvedilol inhibited the activation of SAPK by 53.4±6.5{\%} (P<.05). Under the same conditions, propranolol (1 mg/kg) had no effect on SAPK activation. Taken together, these results suggest that carvedilol prevents myocardial ischemia/reperfusion-induced apoptosis in cardiomyocytes possibly by downregulation of the SAPK signaling pathway, by inhibition of Fas receptor expression, and by β-adrenergic blockade. The former two actions represent novel and important mechanisms that may contribute to the cardioprotective effects of carvedilol.",
keywords = "Apoptosis, Cardiomyocyte, Fas, Ischemia, Reperfusion, Stress-activated protein kinase",
author = "Yue, {Tian Li} and Ma, {Xin Liang} and Xinkang Wang and Romanic, {Anne M.} and Liu, {Gao Lin} and Calvert Louden and Gu, {Juan Li} and Sanjay Kumar and George Poste and Ruffolo, {Robert R.} and Feuerstein, {Giora Z.}",
year = "1998",
month = "2",
day = "9",
language = "English (US)",
volume = "82",
pages = "166--174",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Possible involvement of stress-activated protein kinase signaling pathway and fas receptor expression in prevention of ischemia/reperfusion- induced cardiomyocyte apoptosis by carvedilol

AU - Yue, Tian Li

AU - Ma, Xin Liang

AU - Wang, Xinkang

AU - Romanic, Anne M.

AU - Liu, Gao Lin

AU - Louden, Calvert

AU - Gu, Juan Li

AU - Kumar, Sanjay

AU - Poste, George

AU - Ruffolo, Robert R.

AU - Feuerstein, Giora Z.

PY - 1998/2/9

Y1 - 1998/2/9

N2 - Carvedilol, a new vasodilating β-adrenoceptor antagonist and a potent antioxidant, produces a high degree of cardioprotection in a variety of experimental models of ischemic cardiac injury. Recent clinical studies in patients with heart failure have demonstrated that carvedilol reduces morbidity and mortality and inhibits cardiac remodeling. The present study was designed to explore whether the protective effects of carvedilol on the ischemic myocardium include inhibition of apoptosis of cardiomyocytes and, if so, to determine its mechanism of action. Anesthetized rabbits were subjected to 30 minutes of coronary artery occlusion followed by 4 hours of reperfusion. Detection of apoptosis of cardiomyocytes was based on the presence of nucleosomal DNA fragments on agarose gels (DNA ladder) and in situ nick end labeling. Carvedilol (1 mg/kg IV), administered 5 minutes before reperfusion, reduced the number of apoptotic myocytes in the ischemic area from 14.7±0.4% to 3.4±1.8% (77% reduction, P<.001). Propranolol, administered at equipotent β-blocking dosage, reduced the number of apoptotic myocytes to 8.94±2.1% (39% reduction, P<.05). DNA ladders were observed in the hearts of all six vehicle-treated rabbits but only one of six carvedilol-treated rabbits (P<.01). Immunocytochemical analysis of rabbit hearts demonstrated an upregulation of Fas protein in ischemic cardiomyocytes, and treatment with carvedilol reduced both the intensity of staining as well as the area stained. Myocardial ischemia/reperfusion led to a rapid activation of stress-activated protein kinase (SAPK) in the ischemic area but not in nonischemic regions. SAPK activity was increased from 2.1±0.3 mU/mg (basal) to 8.9±0.8 mU/mg after 30 minutes of ischemia followed by 20 minutes of reperfusion. Carvedilol inhibited the activation of SAPK by 53.4±6.5% (P<.05). Under the same conditions, propranolol (1 mg/kg) had no effect on SAPK activation. Taken together, these results suggest that carvedilol prevents myocardial ischemia/reperfusion-induced apoptosis in cardiomyocytes possibly by downregulation of the SAPK signaling pathway, by inhibition of Fas receptor expression, and by β-adrenergic blockade. The former two actions represent novel and important mechanisms that may contribute to the cardioprotective effects of carvedilol.

AB - Carvedilol, a new vasodilating β-adrenoceptor antagonist and a potent antioxidant, produces a high degree of cardioprotection in a variety of experimental models of ischemic cardiac injury. Recent clinical studies in patients with heart failure have demonstrated that carvedilol reduces morbidity and mortality and inhibits cardiac remodeling. The present study was designed to explore whether the protective effects of carvedilol on the ischemic myocardium include inhibition of apoptosis of cardiomyocytes and, if so, to determine its mechanism of action. Anesthetized rabbits were subjected to 30 minutes of coronary artery occlusion followed by 4 hours of reperfusion. Detection of apoptosis of cardiomyocytes was based on the presence of nucleosomal DNA fragments on agarose gels (DNA ladder) and in situ nick end labeling. Carvedilol (1 mg/kg IV), administered 5 minutes before reperfusion, reduced the number of apoptotic myocytes in the ischemic area from 14.7±0.4% to 3.4±1.8% (77% reduction, P<.001). Propranolol, administered at equipotent β-blocking dosage, reduced the number of apoptotic myocytes to 8.94±2.1% (39% reduction, P<.05). DNA ladders were observed in the hearts of all six vehicle-treated rabbits but only one of six carvedilol-treated rabbits (P<.01). Immunocytochemical analysis of rabbit hearts demonstrated an upregulation of Fas protein in ischemic cardiomyocytes, and treatment with carvedilol reduced both the intensity of staining as well as the area stained. Myocardial ischemia/reperfusion led to a rapid activation of stress-activated protein kinase (SAPK) in the ischemic area but not in nonischemic regions. SAPK activity was increased from 2.1±0.3 mU/mg (basal) to 8.9±0.8 mU/mg after 30 minutes of ischemia followed by 20 minutes of reperfusion. Carvedilol inhibited the activation of SAPK by 53.4±6.5% (P<.05). Under the same conditions, propranolol (1 mg/kg) had no effect on SAPK activation. Taken together, these results suggest that carvedilol prevents myocardial ischemia/reperfusion-induced apoptosis in cardiomyocytes possibly by downregulation of the SAPK signaling pathway, by inhibition of Fas receptor expression, and by β-adrenergic blockade. The former two actions represent novel and important mechanisms that may contribute to the cardioprotective effects of carvedilol.

KW - Apoptosis

KW - Cardiomyocyte

KW - Fas

KW - Ischemia

KW - Reperfusion

KW - Stress-activated protein kinase

UR - http://www.scopus.com/inward/record.url?scp=0032498614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032498614&partnerID=8YFLogxK

M3 - Article

C2 - 9468187

AN - SCOPUS:0032498614

VL - 82

SP - 166

EP - 174

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 2

ER -